NewAmsterdam Pharma Co NV (FRA:KH6) Buildings And Improvements : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Buildings And Improvements?

NewAmsterdam Pharma Co NV Buildings And Improvements Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Buildings And Improvements Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial								-	-	-	-	-

NewAmsterdam Pharma Co NV Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

NAMS:USA KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Co NV Headlines

No Headlines